Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +0.39%85 Return-on-Tangible-Asset is 14.56% as of Jun. 2026, which is 16% above its 10-year median of 12.54. GuruFocus rates ROCO:4105 with a GF Score™ of 85/100 and a GF Value™ of NT$87.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, TTY Biopharm Co ranks better than 89.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. TTY Biopharm Co's annualizedNet Income for the quarter that ended in Jun. 2026 was NT$1,626 Mil. TTY Biopharm Co's average total tangible assets for the quarter that ended in Jun. 2026 was NT$11,167 Mil. Therefore, TTY Biopharm Co's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 14.56%.
The historical rank and industry rank for TTY Biopharm Co's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4105'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.04 Med: 12.54 Max: 16
Current: 15.86
During the past 13 years, TTY Biopharm Co's highest Return-on-Tangible-Asset was 16.00%. The lowest was 9.04%. And the median was 12.54%.
ROCO:4105's Return-on-Tangible-Asset is ranked better than 89.17% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs ROCO:4105: 15.86
TTY Biopharm Co (ROCO:4105) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
TTY Biopharm Co Return-on-Tangible-Asset Related Terms
TTY Biopharm Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4105 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.56% mean?
TTY Biopharm Co (ROCO:4105) has a Return-on-Tangible-Asset of 14.56% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on TTY Biopharm Co and its competitors. This is 16% above median its historical median of 12.54. Over the past decade, TTY Biopharm Co's Return-on-Tangible-Asset has ranged from 9.04 to 16.00. According to the industry distribution chart, TTY Biopharm Co ranks #109 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is TTY Biopharm Co's Return-on-Tangible-Asset too high?
TTY Biopharm Co's current Return-on-Tangible-Asset of 14.56% is 16% above median its 10-year median of 12.54. Over the past 10 years, this metric has ranged from a low of 9.04 to a high of 16.00. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.05. TTY Biopharm Co's value of 14.56% is 377.4% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #109 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #109 out of 1006 companies for Return-on-Tangible-Asset. This places TTY Biopharm Co in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.05. TTY Biopharm Co's value of 14.56% is 377.4% above this benchmark. Historically, TTY Biopharm Co's own Return-on-Tangible-Asset has ranged from 9.04 to 16.00 over the past decade. While the company's 10-year median is 12.54 vs. the industry median of 3.05, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Return-on-Tangible-Asset of 14.56% is 377.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Return-on-Tangible-Asset is 14.56%, which is 16% above median its own 10-year median of 12.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.37, compared to a current price of NT$76.40 — trading 12.6% below its estimated fair value. The current Return-on-Tangible-Asset is 14.56%, which is 16% above median its 10-year median of 12.54 and 377.4% above the Drug Manufacturers industry median of 3.05. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Return-on-Tangible-Asset is 14.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$76.40 is trading 12.6% below its estimated GF Value™ of NT$87.37.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Return-on-Tangible-Asset: 14.56% (16% above median its 10-year median of 12.54)
GF Value™: NT$87.37 vs. price of NT$76.40 (12.6% below fair value)
Industry Position: 377.4% above the Drug Manufacturers median (#109 of 1006)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score
Get the complete analysis for ROCO:4105
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
